Please login to the form below

Not currently logged in
Email:
Password:

Genzyme’s Richard Moscicki joins FDA

Provides regulatory agency with more than 20 years of industry experience

FDA, Richard MoscickiThe US Food and Drug Administration (FDA) has appointed Genzyme's Dr Richard Moscicki to the newly created position of deputy centre director for science operations at its Center for Drug Evaluation and Research (CDER).

Dr Moscicki, who currently serves as senior VP, head of clinical development at Sanofi's Genzyme division, will help lead the CDER in its role to regulate over-the-counter and prescription-only drugs available in the US.

The FDA will benefit from his strong industry background in research, which includes time spent as medical director and chief medical officer at Genzyme.

He also gained regulatory and pharmacovigilance experience at the US-based biotech, serving as its senior VP of biomedical and regulatory affairs from 1996 to 2011.

In his role at the FDA, Dr Moscicki will work with Dr Bob Temple, deputy director for clinical science, and Dr Doug Throckmorton, deputy director for regulatory programmes.

14th February 2013

From: Research, Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...
Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...

Infographics